Peptic Ulcer Drugs Market Research Report Information By Pharmacological class (Proton pump inhibitors (PPs), Anti-histamines, H2 antagonists, Antacids, and Others), By Clinical (Gastric ulcers, Duodenal ulcer, and Esophageal ulcer), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032

Table of Contents

1 Introduction

1.1 Definition

1.2 Scope of Study

1.3 Research Objective

1.4 Assumptions & Limitations

1.5 Market Structure

2 Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

3 Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

3.5 Macroeconomic Indicators

4 Market Factor Analysis

4.1 Porter’s Five Forces model

4.1.1 Bargaining Power of suppliers

4.1.2 Bargaining Power of Customer

4.1.3 Intensity of Competitor’s

4.1.4 Threat of New Entrants

5 Global Peptic Ulcer drugs Market, by Pharmacological class

5.1 Introduction

5.1.2 Proton Pump Inhibitors (PPIs)

5.1.3 Anti-Histamines

5.1.4 H2 antagonists

5.1.5 Antacids

5.1.6 Antibiotics

5.1.7 Others

6 Global Peptic Ulcer drugs Market, by Clinical Application

6.1 Introduction

6.1.1 Gastric ulcers

6.1.2 Duodenal Ulcer

6.1.3 Esophageal Ulcer

7 Global Peptic Ulcer Drugs Market, By Regions

7.1 Introduction

7.1.1 Americas

7.1.1.1 North America

7.1.1.2 South America

7.1.2 Europe

7.1.2.1 Germany

7.1.2.2 France

7.1.2.3 UK

7.1.2.4 Italy

7.1.2.5 Spain

7.1.2.6 Rest of Europe

7.1.3 Asia Pacific

7.1.3.1 Japan

7.1.3.2 China

7.1.3.3 India

7.1.3.4 Republic of Korea

7.1.3.5 Rest of Asia Pacific

7.1.4 Middle East & Africa

8 Company Landscape

8.1 Introduction

8.1.1 Mergers Acquisitions

8.1.2 Collaborations

8.1.3 Release/New Product Launches

8.1.4 Other (Expansion, Updates, Partnership)

9 Company Profile

9.1 Novartis AG

9.1.1 Company Overview

9.1.2 Product/Business Segment Overview

9.1.3 Financials

9.1.4 Key Developments

9.1.5 SWOT Analysis

9.2 Daiichi Sankyo Company Limited

9.2.1 Overview

9.2.2 Product/Business Segment Overview

9.2.3 Financials

9.2.4 Key Developments

9.2.5 SWOT Analysis

9.3 Acetelion Ltd

9.3.1 Overview

9.3.2 Product/Business Segment Overview

9.3.3 Financials

9.3.4 Key Developments

9.3.5 SWOT Analysis

9.4 Boehringer Ingelheim

9.4.1 Overview

9.4.2 Product/Business Segment Overview

9.4.3 Financials

9.4.4 Key Developments

9.4.5 SWOT Analysis

9.5 Sanofi S.A.

9.5.1 Overview

9.5.2 Product/Business Segment Overview

9.5.3 Financials

9.5.4 Key Developments

9.5.5 SWOT Analysis

9.6 Astra Zeneca

9.6.1 Overview

9.6.2 Product/Business Segment Overview

9.6.3 Financials

9.6.4 Key Developments

9.6.5 SWOT Analysis

9.7 Ranbaxy Laboratories Limited, Inc.

9.7.1 Overview

9.7.2 Product/Business Segment Overview

9.7.3 Financials

9.7.4 Key Developments

9.7.5 SWOT Analysis

9.8 Takeda Pharmaceuticals Company Limited

9.8.1 Overview

9.8.2 Product/Business Segment Overview

9.8.3 Financials

9.8.4 Key Developments

9.8.5 SWOT Analysis

9.9 Pfizer Inc.

9.9.1 Overview

9.9.2 Product/Business Segment Overview

9.9.3 Financials

9.9.4 Key Developments

9.9.5 SWOT Analysis

9.9 Helicure AB

9.9.1 Overview

9.9.2 Product/Business Segment Overview

9.9.3 Financials

9.9.4 Key Developments

9.9.5 SWOT Analysis

9.9 Eumedica pharmaceuticals

9.9.1 Overview

9.9.2 Product/Business Segment Overview

9.9.3 Financials

9.9.4 Key Developments

9.9.5 SWOT Analysis

10 Others

11 Appendix

List of Tables

TABLE 1 GLOBAL PEPTIC ULCER DRUGS MARKET, 2020-2027 (USD MILLION)

TABLE 2 GLOBAL PEPTIC ULCER DRUGS MARKET, BY PHARMACOLOGICAL CLASS 2020-2027 (USD MILLION)

TABLE 3 GLOBAL PEPTIC ULCER DRUGS MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL PEPTIC ULCER DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION)

List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 PORTERS FIVE FORCES MODEL

FIGURE 3 GLOBAL PEPTIC ULCER DRUGS MARKET, BY PHARMACOLOGICAL CLASS

FIGURE 4 GLOBAL PEPTIC ULCER DRUGS MARKET, BY CLINICAL APPLICATION

FIGURE 5 GLOBAL PEPTIC ULCER DRUGS MARKET, BY REGION

FIGURE 6 GLOBAL PEPTIC ULCER DRUGS MARKET: COMPANY SHARE ANALYSIS, 2020 (%)